Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe-Reference-Cited by-同舟云学术

Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe

Published:2022-09-06 Issue:1 Volume:25 Page:1068-1075
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Mancuso Maria Elisa¹^ORCID,Castaman Giancarlo²^ORCID,Pochopien Michal³,Aballéa Samuel⁴,Drzewiecka Aleksandra³^ORCID,Hakimi Zalmai⁵^ORCID,Nazir Jameel⁵,Fatoye Francis⁶^ORCID

Affiliation:

1. Centre for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Italy

2. Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Center for Bleeding Disorders, Florence, Italy

3. Creativ-Ceutical, Krakow, Poland

4. Creativ-Ceutical, Rotterdam, The Netherlands

5. Swedish Orphan Biovitrum Ltd, Stockholm, Sweden

6. Faculty of Health and Education, Manchester Metropolitan University, Manchester, UK

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2022.2115777

Reference48 articles.

1. The evolving understanding of factor VIII binding sites and implications for the treatment of hemophilia A

2. National Hemophilia Foundation. Fast facts. 2020. [cited 2020 May]. Available from: https://www.hemophilia.org/About-Us/Fast-Facts.

3. Future of haemophilia outcome assessment: registries are key to optimized treatment

4. The cost of severe haemophilia in Europe: the CHESS study

5. World Federation of Hemophilia. Complications of hemophilia. 2012. [cited 2020 April]; Available from: http://www1.wfh.org/publications/files/pdf-1499.pdf.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emicizumab prophylaxis for people with hemophilia A: Waste estimation and the Brazilian perspective;Saudi Pharmaceutical Journal;2023-12

2. The efficacy of the entire-vial dosing of emicizumab: Real-world evidence on plasma concentrations, bleeds, and drug waste;Research and Practice in Thrombosis and Haemostasis;2023-02